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Background: The purpose of this study is to detect the Parkinson’s disease gene family mRNA relative expression
in the non-small-cell lung cancer (NSCLC) tumor tissue and analyze the association between tumor characteristics
and the Parkinson’s disease gene family.
Methods: Tumor tissue and tumor-adjacent tissue of 114 NSCLC patients were collected and SYBR quantitative
analysis was used to detect the relative expression level of nine Parkinson’s disease gene mRNAs. Then, paired
sample test, two-sided Student’s t-test, or two-sided Wilcoxon rank sum test was performed to analyze the mRNA
relative expression level of nine Parkinson’s disease gene mRNAs in different gender, tumor histology, and tumor
stage.
Results: Overexpression in the tumors was detected in 46/114 (40.35 %) PARK1/4, 74/114 (64.91 %) PARK2, 104/114
(91.23 %) PARK5, 95/114 (83.33 %) PARK6, 80/114 (70.18 %) PARK7, 55/114 (48.25 %) PARK8, 100/114 (87.72 %)
PARK9, 55/114 (48.25 %) PARK15, and 99/114 (86.84 %) glucocerebrosidase (GBA). Five genes PARK5 (91.23 %),
PARK6 (83.33 %), PARK7 (70.18 %), PARK9 (87.72 %), and GBA (86.84 %) were supposed to be overexpressed in the
lung tumor tissues compared with tumor-adjacent tissues. There was no significant difference in PARK1/4, PARK2,
PARK5, PARK9, and GBA mRNA expression by different tumor stage, whereas, PARK6, PARK7, PARK8, and PARK15
mRNA expression were found to have significant difference in the comparison of different tumor stages. The
expression of PARK6 (P = 0.01, P = 0.03) and PARK15 (P < 0.001, P < 0.001) were significantly higher in stages I and II
when compared with stage III, respectively. NSCLC patients in stage I showed the higher expression PARK7
compared to the patients in stage II (P = 0.003).
Conclusions: The high expression of PARK6, PARK7, and PARK15 might lead to the occurrence of a primary NSCLC
tumor, and the tumor with a decreasing expression of these three genes tends to be stages II and III. The results of
our study indicate that the Parkinson’s disease gene family may be a potential marker for the prediction of NSCLC.
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Parkinson’s disease is a chronic, progressive neurological
disorder caused by the degeneration and death of cells
in the substantia nigra [1]. Historically, Parkinson’s dis-
ease was regarded as a sporadic disorder, with little or
no contribution from hereditary factors. However, over
the past 15 years, there has been a step change in our
genetic understanding of the condition. SNCA the so-
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lysis in several large kindreds with familial Parkinson’s
disease [2]. Recent genome-wide association studies have
found that more than a dozen loci (including PARK1/4,
PARK2, PARK5, PARK6, PARK7, PARK8, PARK9, PARK15,
and glucocerebrosidase (GBA)) have been linked with fa-
milial Parkinson’s disease, and currently, upwards of
10 % of all cases of Parkinson’s disease are estimated to
be associated with Parkinson’s disease gene family [3–5].
Fifteen years ago, Møller et al. [6] first reported that
patients with Parkinson’s disease (PD) seem to have a
lower-than-expected rate of lung cancer which has been
reaffirmed by many subsequent epidemiological studiesdistributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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function of the Parkinson’s disease gene family between
these two apparently unrelated diseases. Recent genetic
studies and emerging functional work show that a possible
connection between Parkinson’s disease and lung cancer is
alluded.
Cancer cells are prone to accumulate mutations, not all
of which will necessarily contribute to cancer progression
(these are known as passenger mutations, in contrast to the
pivotal driver mutations that propel cancerous change).
However, when the functional roles of the Parkinson’s
disease gene family are considered, a picture emerges of
considerable pathogenic overlap between these two
apparently unrelated diseases. Currently, several stud-
ies have reported that cell systems are affected by the
same dysfunctional protein in both Parkinson’s disease
and cancer [11–13].
In short, the same mutations can lead either to in-
appropriate neuronal death in Parkinson’s disease when
present in the germ line or to inappropriate cell survival
in cancer when present in somatic cells. SNCA (PARK1
or PARK4) was reported overexpressed in brain [14],
malignant [15], and ovary tumors [16] while low-
expressed or not expressed in those normal and benign
tissues. PARK7 (DJ-1) was reported overexpressed in
the non-small-cell lung cancer (NSCLC) and prostate
cancer cell line [17, 18]. Although many studies have
reported that some Parkinson’s disease gene family are
overexpressed or low-expressed in brain, malignant,
ovary, and colon cancer patients and cell lines, the
expression of the Parkinson’s disease gene family in
NSCLC patients and the association of clinical data are
still unknown.
In this article, we investigated the expression of the
Parkinson’s disease gene family in NSCLC patients and
further analyzed its association with different tumor
histological type, gender, and tumor stage. Our analysis
is at times speculative, and additional experimental re-
search may be required to further identify the associ-
ation between Parkinson’s disease gene family and
NSCLC which might help us to discover the new poten-




All the 114 NSCLC patients in the study were diagnosed
and histopathologically confirmed in our hospital be-
tween Feb 2012 and Apr 2013 and without any other
cancers or previous chemo- or radiotherapy. The 114
patients were aged 18–65 years old (56.4 ± 10.7) at the
time of diagnosis including 50 squamous carcinomas
(SQC), and 64 adenocarcinomas (ADC) and were com-
posed of 72 males and 42 females. This study wasapproved by the institutional review board of Xinqiao
Hospital (2012016), and all patients signed informed
consent.
Dispose of tumor tissue and tumor-adjacent tissue
Tumor tissue and tumor-adjacent tissue were collected
at the time of surgical resection. All the samples were
immediately snap-frozen in liquid nitrogen and stored
at −170 °C before use. Total RNA was extracted follow-
ing a TRIzol extraction protocol (Invitrogen, USA).
Reverse transcription and SYBR quantitative real-time PCR
assay
Total RNA was transcriptioned reversely to cDNA by
using PrimeScript™ RT reagent Kit with gDNA Eraser
(TAKARA, Japan). SYBR (Synergy BrandsSynergy Brands)
quantitative analysis of mRNA expression was used to
investigate the expression of Parkinson’s disease gene
family, including PARK1/4 (SCNA), PARK2 (Parkin),
PARK5 (UCHL1), PARK6 (PINK1), PARK7 (DJ-1), PARK8
(LRRK2), PARK9 (ATP13A2), PARK15 (FBXO7), and GBA
[19], in the tumor tissue and tumor-adjacent tissue.
Primers for SYBR q-PCR were designed and synthesized by
Sangon Biotech (China) (Table 1). PCR reactions (15 μl)
contained 0.25 μl of each primer (10 μM), 7.5 μl SYBR® Pre-
mix Ex Taq TM II 2× (TAKARA, Japan), 6 μl ddH2O, and
1 μl cDNA. The PCR conditions consisted of an initial de-
naturation at 95 °C for 30 s followed by amplification for
40 cycles of 15 s at 95 °C and 50 s at 60 °C, with fluores-
cence acquisition at the end of each extension step. PCR
using primers for β2-microglobulin was performed on each
individual sample as an internal control. The optical density
of each PCR band was measured semi-quantitatively using
Illumina Eco software (Illumina, San Diego, USA).
Statistical analysis
Relative Parkinson’s disease gene family expression was
calculated for each patient. The differences in mean
value of Parkinson’s disease gene family expression in
tumor tissue and tumor-adjacent tissue were analyzed
using paired samples test. The differences in gene ex-
pression between gender, tumor histology, and tumor
stage were analyzed using two-sided Student’s t-test or
two-sided Wilcoxon rank sum test. All statistical ana-
lyses were performed using SPSS 18.0 software (SPSS
Inc.), and P < 0.05 was considered to be statistically
significant.
Results
Relative expression level of Parkinson’s disease gene family
Expression levels of nine Parkinson’s disease genes and a
reference gene were measured in 114 matched pairs of
NSCLCs/adjacent histologically normal lung tissue samples
by real-time q-PCR. According to the relative mRNA
Table 1 Sequence of primers used in Parkinson’s disease gene mRNA real-time q-PCR
Primer GeneBank ID Sequence forward (5′–3′) Sequence reverse (5′–3′) Product (bp)
PARK1/4 SCNA NM000345.3 AAACCAAGGAGGGAGTGGTG CTGTCTTCTGGGCTACTGCTG 117
PARK2 Parkin AB009973.1 CTGACACCAGCATCTTCCAG CCAGTCATTCCTCAGCTCCT 107
PARK5 UCHL1 BC000332.2 GCCAATGTCGGGTAGATGAC AGCGGACTTCTCCTTGCTC 192
PARK6 PINK1 AB053323.1 CAAGAGAGGTCCCAAGCAAC GGCAGCACATCAGGGTAGTC 117
PARK7 DJ-1 D61380.2 TGGCTAAAGGAGCAGAGGAA ATGACCACATCACGGCTACA 127
PARK8 LRRK2 AY792511.1 GAGCACGCCTCCAAGTTATT AGAAGTGACCAACCCACCTG 110
PARK9 ATP13A2 AL354615.1 TGGCTGGCTGACCACTACTAC AGTCTGGCTTTGCTTTCTGG 102
PARK15 FBXO7 AF233225.1 TACCCGACAAGCACTGAACC AAGACGGAACGAACATCCAG 102
GBA D13286.1 CTTCTGCTGGGCTGTTGAGT TACTGTTGGCGAGGGTAGGA 108
β2-microglobulin NM004048.2 ACCCCCACTGAAAAAGATGA ATCTTCAAACCTCCATGATG 114
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vided into five groups (Table. 2). A relative gene expression
ratio (T/N) of 1.5 was considered as positive for overex-
pression in the tumor when compared to the correspond-
ing tumor-adjacent tissue. Values more than 1.5 have been
used as the criterion for overexpression of genes in several
studies employing proteomic analysis [20]. Therefore, over-
expression in the tumors was detected in 46/114 (40.35 %)
PARK1/4, 74/114 (64.91 %) PARK2, 104/114 (91.23 %)
PARK5, 95/114 (83.33 %) PARK6, 80/114 (70.18 %) PARK7,
55/114 (48.25 %) PARK8, 100/114 (87.72 %) PARK9, 55/
114 (48.25 %) PARK15, and 99/114 (86.84 %) GBA. PARK7
(DJ-1) was considered to be overexpressed in primary
NSCLC tissues in a previous study [18], and 70.18 % of the
patients were detected to have PARK7 overexpression in
this study. Then, the five genes PARK5 (91.23 %), PARK6
(83.33 %), PARK7 (70.18 %), PARK9 (87.72 %), and GBA
(86.84 %) were supposed to be overexpressed in the lung
tumor tissue compared with the tumor-adjacent tissue. In-
activating mutations and deletions of PARK2 have been
found in lung cancer [18] and overexpression of PARK15
was also detected in lung squamous cell carcinoma [21];Table 2 The frequency distribution of Parkinson’s disease gene mRNA
Fold PARK1/4 SCNA PARK2 Parkin PARK5 UCHL1 PARK6 PINK1 P
(n = 114) (n = 114) (n = 114) (n = 114) (n
≤0.5 23 18 1 9
(20.18 %) (15.79 %) (0.88 %) (7.89 %)
0.5–1.5 45 22 9 10
(39.47 %) (19.30 %) (7.89 %) (8.77 %) (
≥1.5 46 74 104 95
(40.35 %) (64.91 %) (91.23 %) (83.33 %) (
≥5 2 19 91 45
(1.75 %) (16.67 %) (79.82 %) (39.47 %) (
≥10 0 4 70 16
(0.00 %) (3.51 %) (61.40 %) (14.04 %)
Fold means the fold of relative mRNA gene expression to reference gene β2-microghowever, more than half (64.91 %) of the patients showed
the overexpression of PARK2, and there was only 48.25 %
PARK15-overexpression patients in this study. Their incon-
sistencies in findings may be caused by the small sample
size and different research objects. The relationship be-
tween lung cancer and the expression of the other six genes
PARK1/4, PARK5, PARK6, PARK8, PARK9, and GBA was
first described (Fig. 1).
Associations of tumor characteristics with Parkinson’s
disease genes
Mean values of PARK1/4 (SCNA), PARK2 (Parkin),
PARK5 (UCHL1), PARK6 (PINK1), PARK7 (DJ-1), PARK8
(LRRK2), PARK9 (ATP13A2), PARK15 (FBXO7), and GBA
relative mRNA expression according to gender, tumor hist-
ology, and each clinical stage are summarized in Table 3.
Significant statistical difference of relative mRNA expres-
sion level of these nine genes was detected in the compari-
son between tumor tissue and tumor-adjacent tissue. The
relative expression of these nine gene mRNAs showed no
significant difference between the male groups and female
groups. However, the ADC group showed significantlyrelative expression
ARK7 DJ-1 PARK8 LRRK2 PARK9 ATP13A2 PARK15 FBXO7 GBA
= 114) (n = 114) (n = 114) (n = 114) (n = 114)
9 22 5 14 6
(7.89 %) (19.30 %) (4.39 %) (12.28 %) (5.26 %)
25 37 9 45 9
21.93 %) (32.46 %) (7.89 %) (39.47 %) (7.89 %)
80 55 100 55 99
70.18 %) (48.25 %) (87.72 %) (48.25 %) (86.84 %)
14 15 66 9 56
12.28 %) (13.16 %) (57.89 %) (7.89 %) (49.12 %)
2 2 39 0 23
(1.75 %) (1.75 %) (34.21 %) (0.00 %) (20.18 %)
lobulin
Fig. 1 The relative expression of Parkinson’s disease gene mRNA in NSCLC patients. Blue, red, and green columns mean the ≤0.5-fold, 0.5–1.5-fold,
and ≥1.5-fold of mRNA relative expression compared with tumor-adjacent tissue, respectively
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expression than the SQC group, and no significant differ-
ence was found in the other seven genes. There was no sig-
nificant difference in PARK1/4, PARK2, PARK5, PARK9,
and GBA mRNA expression by different tumor stage,
whereas PARK6, PARK7, PARK8, and PARK15 mRNA
expression were found to have significant difference in
the comparison of different tumor stages. The expres-
sion of PARK6 (P = 0.01, P = 0.03) and PARK15 (P <
0.001, P < 0.001) were significantly higher in stages I
and II when compared with stage III, respectively.
NSCLC patients in stage I showed the higher expression
PARK7 compared to the patients in stage II (P = 0.003).
Interestingly, the relative expression of PARK8 for the
NSCLC patients in stage II was higher than that in stages I
(P = 0.04) and III (P < 0.001).
Discussion
The curious cancer pattern in certain neurological con-
ditions has drawn increasing attention as converging evi-
dence suggests that one family of diseases may provide
protection against the other. Over 50 years ago, it was
anecdotally noted that patients with Parkinson’s disease
(PD) seem to have a lower-than-expected rate for most
cancers [22]. Cancer is characterized by unlimited cellu-
lar proliferation, while PD is a process of premature cell
death. In this sense, the diseases appear to be opposing
ends of the same spectrum. In fact, they share many
genes and biological pathways, and these are often regu-
lated in different directions. The main cell components
(protein degradation, cell cycle, mitochondria, PI3K–
AKT–mTOR pathway and inflammation) and the main
Parkinson’s-disease-associated proteins (parkin, PTEN-
induced putative kinase 1 (PINK1), DJ-1, leucine-rich re-
peat kinase 2 (LRRK2), glucocerebrosidase (GBA), and
F-box protein 7 (FBXO7)) are depicted with the multiple
interactions that exist between them.Neurons and cancer cells are fundamentally different
in how they use mitochondria. Whereas neurons use
oxidative phosphorylation to generate ATP, cancer cells
use glycolysis to a greater extent, which is partly ex-
plained by the hypoxic tumor environment. However,
this alternative metabolism persists in tumor cells even
in the presence of oxygen, as originally observed by
Warburg nearly a century ago [23]. So, mitochondrial
dysfunction has long been implicated in the develop-
ment of cancer, and this perspective is now undergoing
a renaissance. Functional studies of Parkinson’s disease
genes indicate that the mTOR (mammalian target of
rapamycin) pathway probably has a major bearing on
neurodegeneration [24–26]. The mTOR pathway is a
central regulator of cell growth and proliferation that
mainly functions through the modulation of protein syn-
thesis. The central importance of this pathway for cancer
biology is reflected by the fact that an mTOR inhibitor,
sirolimus (also known as rapamycin), is already in use in
oncology practice, and several trials of PI3K and AKT in-
hibitors are underway [27–29]. Inflammation promotes
tumorigenesis and progression by providing growth
factors that sustain proliferative signalling and survival
factors that limit cell death. Chronic inflammation is
regarded as an enabling characteristic in cancer, and re-
cent work suggests that a similar mechanism might drive
pathological change in PD conditions [30, 31].
To date, only one study has examined the expression
of the PARK7 in primary NSCLCs [18]. However, no com-
parison was made between expression levels in matched
tumor/normal pairs for the Parkinson’s disease gene family.
The objective of the current study was to determine
whether the Parkinson’s disease gene family is overex-
pressed in NSCLCs as compared to adjacent histologically
normal lung tissue samples and further determine the rela-
tionship of the expression levels to gender, tumor sub-type,
and tumor stage. One hundred and fourteen matched























































































































































































































































































































I–II means the compare between stages I and II, II–III means the compare between stages II and III, I–III means the compare between stages I and III
a: Test for equality of medians between different gene relative expression and different sex: a1two-sided Student’s t-test; a2two-sided Wilcoxon rank sum test
b: Test for equality of medians between different gene relative expression and different tumor histology: b1two-sided Student’s t-test; b2two-sided Wilcoxon rank sum test
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real-time q-PCR analysis for expression of PARK1/4
(SCNA), PARK2 (Parkin), PARK5 (UCHL1), PARK6
(PINK1), PARK7 (DJ-1), PARK8 (LRRK2), PARK9
(ATP13A2), PARK15 (FBXO7), and GBA mRNA. Using a
value of 1.5 as the criterion for mRNA overexpression, ele-
vated levels of Parkinson’s disease gene family mRNA in
the NSCLC were detected and performed in Table 2.
PARK7 (DJ-1) was considered to be overexpressed in
primary NSCLC tissues in a previous study, and 70.18 % of
the patients were detected to have PARK7 overexpression
in this study. Then, the five genes PARK5 (91.23 %), PARK6
(83.33 %), PARK7 (70.18 %), PARK9 (87.72 %), and GBA
(86.84 %) were supposed to be overexpressed in the lung
tumor tissue compared with the tumor-adjacent tissue.
There was no apparent correlation between the Parkinson’s
disease gene family ratio (T/N) of different genders.
PARK6, PARK7, PARK8, and PARK15 mRNA expression
were found to have significant difference in the compari-
son of different tumor stages. The high expression of
PARK6, PARK7, and PARK15 might lead to the occur-
rence of a primary tumor, but the tumor with a decreas-
ing expression of PARK6 and PARK15 tends to be the
stages II and III tumor. Only PARK2 and PARK7 in the
ADC group showed significantly higher mRNA expres-
sion than those in the SQC group, which revealed that
PARK2 and PARK7 may play a more important role in
normal lung cells that transform into adenocarcinomas
than those that become squamous cell carcinomas.
Adjacent normal lung tissue is the best control we could
obtain for this study. Although the tissue was observed to
be histologically normal, it is unclear what molecular
changes have occurred in these cells and, therefore, how
far along these cells are with respect to developing into
cancer cells.
Conclusions
The data presented in this manuscript suggest that fur-
ther characterization of the cells that comprise both lung
tumors and adjacent histologically normal tissue is war-
ranted to establish the molecular mechanisms resulting
in overexpression of the Parkinson’s disease gene family.
Overall, the results of our study indicate that the Parkin-
son’s disease gene family may be a potential marker for
the prediction of NSCLC. In a reciprocal manner, func-
tional studies in a Parkinson’s disease context may provide
novel insights into the role of cancer-associated genes.
Ultimately, perhaps there will be therapeutic agents that
can target both conditions.Additional file
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